Analyst Reco. RxSight, Inc.

Equities

RXST

US78349D1072

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
60.21 ^USD	+2.42%		-3.18%	+49.33%

May. 13	RxSight Raises $115 Million From Public Offering of Shares	MT
May. 07	Wells Fargo Adjusts RxSight Price Target to $68 From $61, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Adjusts RxSight Price Target to $68 From $61, Maintains Overweight Rating	May. 07	MT
Oppenheimer Adjusts RxSight Price Target to $72 From $61, Maintains Outperform Rating	May. 07	MT
Needham Adjusts Price Target on RxSight to $75 From $64, Maintains Buy Rating	May. 07	MT
BTIG Adjusts Price Target on RxSight to $72 From $61, Maintains Buy Rating	May. 07	MT
Rxsight Insider Sold Shares Worth $526,913, According to a Recent SEC Filing	May. 02	MT
Rxsight Insider Sold Shares Worth $997,946, According to a Recent SEC Filing	Apr. 02	MT
Needham Raises Price Target on RxSight to $64 From $53, Maintains Buy Rating	Feb. 29	MT
Oppenheimer Adjusts RxSight Price Target to $61 From $54, Maintains Outperform Rating	Feb. 29	MT
Stifel Adjusts Price Target on RxSight to $54 From $45, Maintains Buy Rating	Feb. 12	MT
Oppenheimer Raises RxSight Price Target to $54 From $50, Maintains Outperform Rating	Jan. 29	MT
Oppenheimer Raises RxSight Price Target to $50 From $46, Maintains Outperform Rating	Jan. 16	MT
Oppenheimer Ups Price Target on RxSight to $46 From $38, Maintains Outperform Rating	Jan. 08	MT
Needham Adjusts Price Target on RxSight to $41 From $35, Keeps Buy Rating	Jan. 08	MT
Wells Fargo Upgrades RxSight to Overweight From Equalweight, Price Target is $42	Dec. 13	MT
Stifel Starts RxSight With Buy Rating, $40 Price Target	Dec. 12	MT
Needham Adjusts RxSight Price Target to $30 From $36, Maintains Buy Rating	Nov. 10	MT
Oppenheimer Adjusts RxSight Price Target to $34 From $29, Maintains Outperform Rating	23-08-08	MT
Needham Adjusts Price Target on RxSight to $34 From $27, Maintains Buy Rating	23-07-12	MT
BTIG Adjusts Price Target on RxSight to $29 From $25, Maintains Buy Rating	23-06-05	MT
Wells Fargo Adjusts Price Target on RxSight to $27 From $17, Maintains Equalweight Rating	23-06-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. RxSight, Inc.

Equities

RXST

US78349D1072

Analyst Reco.

Filters